Abstract: A wearable device, where the wearable device includes at least two working modes. The at least two working modes include a first working mode and a second working mode. The wearable device receives a user operation, the wearable device starts the first working mode in response to a first operation of a user to collect first activity data, where the first activity data is daily activity data of the user, and the wearable device starts the second working mode in response to a second operation of the user to collect second activity data, where the second activity data is professional exercise data of the user.

Abstract: An electronic device establishes a connection to an audio device, the electronic device displays a first image, the audio device outputs audio data synchronized with the first image, the electronic device receives a projection operation, and the electronic device sends projection information of the first image to a display device based on the projection operation. The display device displays the first image based on the projection information, and the audio device outputs the audio data synchronized with the first image.

Abstract: An electronic device establishes a connection to an audio device, the electronic device displays a first image, the audio device outputs audio data synchronized with the first image, the electronic device receives a projection operation, and the electronic device sends projection information of the first image to a display device based on the projection operation. The display device displays the first image based on the projection information, and the audio device outputs the audio data synchronized with the first image.

Abstract: A human monoclonal antibody that specifically binds tumor necrosis factor receptor 2 (TNFR2), and a defucosylated form of the antibody, are described. The TNFR2-specific antibody was isolated from a human scFv phage display antibody library. The disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2+ CD4+ T regulatory cells in a dose- and time-dependent manner. Methods of using the TNFR2 antibodies, such as for tumor immunotherapy, are described.

Abstract: A wearable device, where the wearable device includes at least two working modes. The at least two working modes include a first working mode and a second working mode. The wearable device receives a user operation, the wearable device starts the first working mode in response to a first operation of a user to collect first activity data, where the first activity data is daily activity data of the user, and the wearable device starts the second working mode in response to a second operation of the user to collect second activity data, where the second activity data is professional exercise data of the user.

Abstract: Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.

Abstract: A human monoclonal antibody that specifically binds tumor necrosis factor receptor 2 (TNFR2), and a defucosylated form of the antibody, are described. The TNFR2-specific antibody was isolated from a human scFv phage display antibody library. The disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2+ CD4+ T regulatory cells in a dose- and time-dependent manner. Methods of using the TNFR2 antibodies, such as for tumor immunotherapy, are described.

Abstract: Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.

Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

Abstract: The present disclosure relates to a method, apparatus and system for processing a configuration update failure, belonging to the field of communications. The method includes: setting a times threshold for receiving an eNB configuration update failure message; sending an eNB configuration update message to an MME or a neighboring eNB after configuration information is updated; receiving, from the MME or the neighboring eNB, an eNB configuration update failure message including a Time-To-Wait IE; calculating the times for receiving the eNB configuration update failure message; comparing the calculated times for receiving the eNB configuration update failure message with the set times threshold to determine whether the calculated times exceed the set times threshold; and stopping sending the eNB configuration update message if the calculated times exceed the set times threshold.

Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

Abstract: The present disclosure relates to a method, apparatus and system for processing a configuration update failure, belonging to the field of communications. The method includes: setting a times threshold for receiving an eNB configuration update failure message; sending an eNB configuration update message to an MME or a neighboring eNB after configuration information is updated; receiving, from the MME or the neighboring eNB, an eNB configuration update failure message including a Time-To-Wait IE; calculating the times for receiving the eNB configuration update failure message; comparing the calculated times for receiving the eNB configuration update failure message with the set times threshold to determine whether the calculated times exceed the set times threshold; and stopping sending the eNB configuration update message if the calculated times exceed the set times threshold.

Abstract: A method and system for resource configuration in semi-persistent scheduling of a VOIP service is disclosed. The system includes a call party and an eNB. The method includes: an eNB storing a corresponding relationship of a size of a voice data packet and the number of RB resources; a call party sending to the eNB an information of the size of the voice data packet required by adopting a voice encoding algorithm after determining the voice encoding algorithm used in a call; and the eNB searching out the corresponding number of the RB resources from the corresponding relationship according to the size of the voice data packet after receiving the information of the size of the voice data packet, and then allocating the RB resources corresponding to the corresponding number to said call party. The present invention improves the utilization ratio of the radio resources and the call quality.

Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

Abstract: The invention provides compositions and methods of enhancing an immune response in a subject. The compositions comprise eosinophil derived-neurotoxin (EDN) and/or human pancreatic ribonuclease (hPR), which can be used as adjuvants to elicit an enhanced immune response in a subject.

Abstract: The present invention provides a method of enhancing an immune response in a subject, comprising administering an effective amount of LL-37. Moreover, the present invention provides a method of enhancing in a subject an immune response to a vaccine, comprising administering to the subject an effective amount of LL-37 with a vaccine. Further provided is a method of detecting a compound that decreases an immune response in a subject. A method of treating an autoimmune disease in a subject is thus provided. Also provided is a vaccine comprising an immunogen and LL-37.

Abstract: The present invention provides a method of enhancing an immune response in a subject, comprising administering an effective amount of LL-37. Moreover, the present invention provides a method of enhancing in a subject an immune response to a vaccine, comprising administering to the subject an effective amount of LL-37 with a vaccine. Further provided is a method of detecting a compound that decreases an immune response in a subject. A method of treating an autoimmune disease in a subject is thus provided. Also provided is a vaccine comprising an immunogen and LL-37.